BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...Sanofi’s biggest acquisition since Ablynx broadens its MS portfolio, allows pharma to pursue additional CNS indications...
...billion ($2.4-$5.9 billion) range (see “Writing on the Wall”).It’s Sanofi’s biggest acquisition since it bought Ablynx N.V....
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with...
...€23 million ($26.9 million) series A financing led by Fund+, will pursue therapies for COVID-19. Ablynx N.V....
...in 2001 and was acquired 17 years later by Sanofi (Euronext:SAN; NASDAQ:SNY) for $4.8 billion. Ablynx’s...
BioCentury | Jun 16, 2020
Finance

Barcelona’s Ona takes aim at metastasis with €30M series A

...CEO Valerie Vanhooren told BioCentury. Vanhooren is a former project leader at Belgian antibody company Ablynx N.V....
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...is using AI to develop proteins, appointed Edwin Moses as chairman. Moses was CEO of Ablynx N.V....
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...platform as well as its nanobody platform, which it acquired via its 2018 acquisition of Ablynx N.V....
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...based on single-domain antibody fragments; Sanofi acquired the program last year via its takeout of Ablynx N.V....
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

...life science companies, among them substantial holdings in Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and until recently Ablynx...
...to Become Europe’s Next Big Biotech ”). The firm was also the largest shareholder in Ablynx...
BioCentury | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

...Wittendorff as head of manufacturing. He was senior director, CMC manufacturing and product supply at Ablynx...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...portions of rounds raised before 2012 are not included below; (B) Sanofi (Euronext:SAN; NASDAQ:SNY) acquired Ablynx N.V....
...immunotherapies Inflammation Axovant Gene Therapies Ltd. (NASDAQ:AXGT) $591.0 $591.0 Gene therapy Endocrine/ metabolic, neurology, musculoskeletal Ablynx...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...hired Gino Van Heeke as CSO. He was senior director, discovery and early development at Ablynx N.V....
Items per page:
1 - 10 of 398
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...Sanofi’s biggest acquisition since Ablynx broadens its MS portfolio, allows pharma to pursue additional CNS indications...
...billion ($2.4-$5.9 billion) range (see “Writing on the Wall”).It’s Sanofi’s biggest acquisition since it bought Ablynx N.V....
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with...
...€23 million ($26.9 million) series A financing led by Fund+, will pursue therapies for COVID-19. Ablynx N.V....
...in 2001 and was acquired 17 years later by Sanofi (Euronext:SAN; NASDAQ:SNY) for $4.8 billion. Ablynx’s...
BioCentury | Jun 16, 2020
Finance

Barcelona’s Ona takes aim at metastasis with €30M series A

...CEO Valerie Vanhooren told BioCentury. Vanhooren is a former project leader at Belgian antibody company Ablynx N.V....
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...is using AI to develop proteins, appointed Edwin Moses as chairman. Moses was CEO of Ablynx N.V....
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...platform as well as its nanobody platform, which it acquired via its 2018 acquisition of Ablynx N.V....
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...based on single-domain antibody fragments; Sanofi acquired the program last year via its takeout of Ablynx N.V....
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

...life science companies, among them substantial holdings in Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and until recently Ablynx...
...to Become Europe’s Next Big Biotech ”). The firm was also the largest shareholder in Ablynx...
BioCentury | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

...Wittendorff as head of manufacturing. He was senior director, CMC manufacturing and product supply at Ablynx...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...portions of rounds raised before 2012 are not included below; (B) Sanofi (Euronext:SAN; NASDAQ:SNY) acquired Ablynx N.V....
...immunotherapies Inflammation Axovant Gene Therapies Ltd. (NASDAQ:AXGT) $591.0 $591.0 Gene therapy Endocrine/ metabolic, neurology, musculoskeletal Ablynx...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...hired Gino Van Heeke as CSO. He was senior director, discovery and early development at Ablynx N.V....
Items per page:
1 - 10 of 398